Endocrine Abstracts

JOINT2163

Introduction: Tirzepatide is a novel dual GLP-1 and GIP receptor agonist that has demonstrated promising results in managing obesity and type 2 diabetes. By targeting both insulin secretion and glucagon suppression, tirzepatide helps improve metabolic control and reduce body weight, making it an exciting therapeutic option for patients with high body mass index (BMI) and related comorbidities.

Objective: To assess the real-world effects of tirzepatide (5 mg dose) on weight, LDL cholesterol, and basal glucose levels in patients with a mean BMI of 45.7.

Study Design: Prospective observational study.

• Participants: 20 subjects (4 males).

• Mean Age: 49.7 years.

• Mean BMI: 45.7.

Intervention.

• Tirzepatide 5 mg administered for 3 months.

Results: • Mean Weight Reduction: 9.9 kg.

• Mean LDL Reduction: 23.3 mg/dl.

• Mean Basal Glucose Reduction: 10.3 mg/dl.

Conclusion: In this real-world observational study, tirzepatide demonstrated significant reductions in weight, LDL cholesterol, and basal glucose levels after 3 months of treatment.